Infection à Mycobacterium avium simulant un adénocarcinome pulmonaire : un potentiel piège diagnostique

Fiogbe, Attannon Arnauld; Liistro, Giuseppe; Hoton, Delphine; Pieters, Thierry

doi:10.1016/j.pneumo.2015.08.003

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2020, American Thoracic Society, European Respiratory Society, and other published an official clinical practice guidelines for the treatment of MAC [ 22 ]. According to the guidelines, MAC requires the presence of pulmonary and systemic symptoms, nodules/cavities on Chest X-ray or bronchiectasis with multiple small nodules on CT, with greater than 2 positive sputum cultures or 1 positive bronchiolar lavage or 1 positive biopsy [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients

Munjal

Gao

et al. 2021

Clinics and Practice

View full text Add to dashboard Cite

Although there has been a drastic decline in the cases of Tuberculosis in the United States, the prevalence of infections caused by Mycobacterium avium Complex (MAC) has steadily increased in the past decades. Mycobacterium avium (M. avium) is one of the most abundant microorganisms in the MAC species. The mycobacterium genus is divided into two major groups: tuberculosis causing mycobacteria and non-tuberculous mycobacteria. MAC is most prominent among the non-tuberculous mycobacteria. MAC is an opportunistic pathogen that is present in soil, water, and droplets in the air. MAC infections can result in respiratory disease and can disseminate in affected patients. MAC infections are especially prevalent in patients with preexisting respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD). COPD is one of the most common lung conditions in the world with the primary cause being smoking in developed countries. COPD involves chronic inflammation of lung tissue resulting in increased susceptibility to infection. There is a lack of research regarding the pathophysiology that leads COPD patients to be susceptible to MAC infection. Our review paper therefore aims to investigate how the pathogenicity of MAC bacteria and immune decline seen in COPD patients leads to a greater susceptibility to MAC infection among COPD patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients

Munjal

Gao

et al. 2021

Clinics and Practice

View full text Add to dashboard Cite

show abstract

“…Nodular bronchiectatic disease forms bronchiectasis and small nodules in the middle lobes of the lungs. In accordance with the guidelines, MAC infection diagnosis requires the presence of pulmonary and systemic symptoms, a chest X-ray showing nodules/cavities or a CT scan showing bronchiectasis with nodules, and a lab culture of sputum from the lungs [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Additive Effects of Cyclic Peptide [R4W4] When Added Alongside Azithromycin and Rifampicin against Mycobacterium avium Infection

Kelley,

Sasaninia,

Abnousian

et al. 2023

Pathogens

View full text Add to dashboard Cite

Mycobacterium avium (M. avium), a type of nontuberculous mycobacteria (NTM), poses a risk for pulmonary infections and disseminated infections in immunocompromised individuals. Conventional treatment consists of a 12-month regimen of the first-line antibiotics rifampicin and azithromycin. However, the treatment duration and low antibiotic tolerability present challenges in the treatment of M. avium infection. Furthermore, the emergence of multidrug-resistant mycobacterium strains prompts a need for novel treatments against M. avium infection. This study aims to test the efficacy of a novel antimicrobial peptide, cyclic [R4W4], alongside the first-line antibiotics azithromycin and rifampicin in reducing M. avium survival. Colony-forming unit (CFU) counts were assessed after treating M. avium cultures with varying concentrations of cyclic [R4W4] alone or in conjunction with azithromycin or rifampicin 3 h and 4 days post-treatment. M. avium growth was significantly reduced 4 days after cyclic [R4W4] single treatment. Additionally, cyclic [R4W4]–azithromycin and cyclic [R4W4]–rifampicin combination treatments at specific concentrations significantly reduced M. avium survival 3 h and 4 days post-treatment compared with single antibiotic treatment alone. These findings demonstrate cyclic [R4W4] as a potent treatment method against M. avium and provide insight into novel therapeutic approaches against mycobacterium infections.

show abstract

Infection à Mycobacterium avium simulant un adénocarcinome pulmonaire : un potentiel piège diagnostique

Cited by 2 publications

References 10 publications

Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients

Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients

Additive Effects of Cyclic Peptide [R4W4] When Added Alongside Azithromycin and Rifampicin against Mycobacterium avium Infection

Contact Info

Product

Resources

About